OnKure Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

OKUR$3.39+6.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(in thousands)

	Three Months Ended
	March 31,
	2025	2024
Cash flows from operating activities:
Net loss	$(15,925)	$(9,536)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	2,745	107
Depreciation and amortization	118	114
Amortization of right-of-use asset - operating	94	37
Change in operating assets and liabilities:
Prepaid and other assets	731	437
Accounts payable, accrued and other liabilities	(1,678)	(1,738)
Lease liabilities	(130)	(50)
Other long-term liabilities	40	—
Net cash used in operating activities	(14,005)	(10,629)
Cash flows from investing activities:
Purchases of property and equipment	(18)	(9)
Net cash used in investing activities	(18)	(9)
Cash flows from financing activities:
Payment of issuance costs associated with the Concurrent Financing	(37)	—
Payment of reverse recapitalization transaction costs	(40)	—
Proceeds from the issuance of common stock in connection with equity plans	—	10
Net cash (used in) provided by financing activities	(77)	10
Net decrease in cash and cash equivalents	(14,100)	(10,628)
Cash and cash equivalents, beginning of period	110,761	29,876
Cash and cash equivalents, end of period	$96,661	$19,248
Supplemental cash flow information:
Interest paid	$—	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.